Management of Severe Azole‑Resistant Vulvovaginal Candidiasis with Perineal Extension
Diagnosis
- Resistance of a vulvovaginal infection to both clotrimazole and miconazole strongly suggests infection with Candida glabrata, which accounts for roughly 10–20 % of recurrent cases and exhibits intrinsic reduced susceptibility to azoles. 2
- Extension of the infection to the perineal skin and proximal thigh indicates severe disease, which is associated with lower clinical response rates to short‑course regimens and therefore requires a prolonged treatment course. 3
First‑Line Antifungal Therapy (Vaginal Component)
- Intravaginal boric acid 600 mg (one gelatin capsule) administered daily for 14 days is recommended as the primary therapy for confirmed or suspected C. glabrata vulvovaginitis after azole failure. 5
Treatment of Perineal and Thigh Extension (Cutaneous Component)
- Apply a topical azole cream (clotrimazole 1 % or miconazole 2 %) to the involved perineal and thigh skin twice daily while the intravaginal boric‑acid regimen is ongoing. 5
- Continue the topical skin treatment for a minimum of 7–14 days and until complete resolution of cutaneous lesions. 2
Critical Pitfalls to Avoid
- Short‑course (1–3 day) regimens are ineffective for severe vulvovaginitis with extensive erythema, edema, excoriation, or tissue extension; a minimum of 7–14 days of therapy is required. 3
- Systemic oral azole therapy is not recommended for azole‑resistant vulvovaginal candidiasis because resistance extends to oral agents and systemic absorption does not improve outcomes for localized mucosal infection. 5
Special Considerations for Severe Disease
- Optimize underlying predisposing conditions (e.g., uncontrolled diabetes, chronic corticosteroid use) because affected patients typically need a longer treatment duration (≥7 days, often 14 days). 2
- Topical 17 % flucytosine cream, alone or combined with 3 % amphotericin B cream, may be used as an alternative; this carries a weak recommendation and should be prescribed after specialist referral. 2
- Non‑fluconazole topical azoles (e.g., clotrimazole, miconazole) for 7–14 days can be attempted but are less effective against C. glabrata than against C. albicans. 2
Follow‑Up and Monitoring
- Advise patients to return for evaluation if symptoms persist or recur within two months after completing therapy. 5
Partner Management
- Routine treatment of sexual partners is not required because vulvovaginal candidiasis is not a sexually transmitted infection. 5
- Male partners who develop symptomatic balanitis may benefit from topical antifungal therapy to relieve their own symptoms. 5